The short answer
Have your prescriber review red yeast rice before combining it with atorvastatin. Products containing appreciable monacolin K add statin-like exposure and could overlap in harmful effects. The inspected combination studies do not establish whether adding these products increases liver-injury risk with atorvastatin; their short follow-up also cannot rule out harm.
What this answer covers
Oral red yeast rice supplements with atorvastatin. Monacolin content and additional ingredients determine how closely a studied product matches a bottle.
- Supplement or preparation
- red yeast rice
- Medication ingredient
- atorvastatin
Why can a supplement overlap with a statin?
Red yeast rice can contain monacolin K, which is chemically identical to lovastatin. Products vary greatly in this content, and some contain very little. Consequently, the supplement name alone does not tell you how much additional statin-like exposure it provides.
What does the combination research show?
A one-month trial added a specified multi-ingredient red yeast rice tablet to routine statin treatment. Liver tests were comparable between groups. The study involved different statins and was short, so it cannot isolate an atorvastatin-specific injury rate or exclude uncommon delayed problems.
Is liver injury therefore proven or ruled out?
Monacolin K can cause statin-like liver and muscle effects. Whether adding a particular red yeast rice product increases liver-injury risk during atorvastatin treatment remains uncertain. The short combination studies cannot resolve uncommon or delayed harm. A prescriber can assess possible duplicate therapy and your other risk factors.
Would taking it at another time solve the problem?
A few hours of separation has not been shown to prevent overlapping statin-like effects. Bring the product label and reason for adding it to your clinician. Seek advice for muscle symptoms or signs of liver trouble, and do not replace prescribed cholesterol treatment with the supplement yourself.
Evidence and practical considerations
Side effects & toxicity
Have your prescriber review red yeast rice before combining it with atorvastatin. Products containing appreciable monacolin K add statin-like exposure and could overlap in harmful effects. The inspected combination studies do not establish whether adding these products increases liver-injury risk with atorvastatin; their short follow-up also cannot rule out harm.
- Exact scope
- Oral red yeast rice supplements with atorvastatin. Monacolin content and additional ingredients determine how closely a studied product matches a bottle. with Exact RxNorm 83367, IN, atorvastatin. LIPITOR contains atorvastatin calcium trihydrate, with strength expressed as atorvastatin active moiety in the label. This is the explicit salt-to-IN bridge.
- Medication form and route
- oral
What remains uncertain
- The studies do not establish the incremental liver-injury risk of adding the specified red yeast rice product to atorvastatin. Product composition, short follow-up and limited safety comparisons prevent both confirming that risk and excluding harm. General monacolin toxicity supports caution but is not direct proof of an added exact-pair effect.
Factors that may matter: Exact preparation, dose, other medicines and baseline clinical condition matter..
Read the supporting source summaries
Source 1: government clinical information
nccih.nih.gov · Source check Sep 10, 2026
Population: People using red yeast rice products.
Products with substantial monacolin K can produce statin-like muscle, liver and kidney effects.
How this applies: Restricted to the exact identities and conditions described in this article.
General product hazard does not establish an increased exact-pair liver-injury rate; no guaranteed safe monacolin level is supplied.
Source 2: regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral atorvastatin.
Provides grapefruit and lipid-modifying niacin precautions, symptom monitoring and once-daily administration with or without food.
How this applies: Restricted to the exact identities and conditions described in this article.
Absence of an ingredient from the label is not a negative interaction study. No pectin, oat bran or Panax-specific human effect size is supplied.
Source 3: original human study
bmcnutr.biomedcentral.com · Source check Sep 10, 2026
Population: 92 reported participants receiving routine statin therapy.
End-of-study liver tests were comparable. Total cholesterol changed, but the LDL difference was not significant.
How this applies: Restricted to the exact identities and conditions described in this article.
Mixed statin treatment, multi-ingredient product, short duration, baseline lipid imbalance and reporting inconsistencies. Does not exclude rare injury or quantify atorvastatin-specific risk.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original-source assessment and consumer article prepared; exact claim dispositions, neutral findings and preparation limits recorded. | |
| Clinical sign-off is pending and no publication approval is asserted. | |
| Clarified evidence limits and source details after an independent editorial audit. Clinical review is still pending. | |
| Research summary published |
Article revision: 95efd2a6307d4752
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.